Background
T2DM
TYPE 2 DIABETES MELLITUS
The prevalence of type 2 diabetes mellitus (T2DM) has increased markedly with an estimated number of 347 million individuals worldwide in 2008, and forecasted to increase to 7079 individuals per 100, 000 by 2030 [Dipeptidyl peptidase-4 inhibitors (DPP-4i) could improve glycemic control by preventing the rapid degradation of incretin hormones and inhibiting glucagon secretion [This is the first phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and long-term safety of fotagliptin in treatment-naive T2DM patients uncontrolled with diet and exercise intervention, comprising 24 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 52 weeks.